BridgeMD
New treatment option for Bronchiectasis
Official title Clinical Study on the Treatment of Stable Bronchiectasis With Bailing Capsules Combined With Guben Kechuan Granules
ClinicalTrials.gov ID: NCT07114120
What this study is testing
What is Bailing Capsules in combination Guben Kechuan Granules?
Bailing Capsules in combination Guben Kechuan Granules is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for bronchiectasis.
Also referred to as Bailing Capsules, Guben Kechuan Granules.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The goal of this clinical trial is to learn if Bailing Capsules in combination Guben Kechuan Granules works to treat stable bronchiectasis in adults.It will also learn about the safety of Bailing Capsules in combination Guben Kechuan Granules The main questions it aims to answer are: Does Bailing Capsules in combination Guben Kechuan Granules lower the number of acute exacerbation in patients with stable bronchiectasis? The safety of the combination of Bailing Capsules and Guben Kechuan Granules ?
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- 18-80 years old, gender not limited;
- It conforms to the Western medical diagnosis of bronchiectasis;
- There has been no acute exacerbation or respiratory tract infection in the past 4 weeks. (Acute exacerbation is defined as the deterioration of three...
- There have been at least two documented acute exacerbations in the past year, prescribed by doctors and diagnosed as signs and symptoms of...
- Pulmonary function tests can be conducted, and there is evidence of airflow limitation when screening vital capacity (FEV1/FVC ratio \<70%, and...
You likely can't join if
- Dry bronchiectasis mainly characterized by hemoptysis;
- Bronchiectasis caused by cystic fibrosis, allergic bronchopulmonary aspergillosis, etc;
- Previous respiratory diseases other than bronchiectasis (such as bronchial asthma, lung cancer, active pulmonary tuberculosis, interstitial lung...
- Combined with serious diseases of the heart, liver, kidneys, digestive system, blood system, etc., evaluated by the researcher, including but not...
- Abnormal liver function was found in the patient screening examination, with the following criteria: total bilirubin \> 1.5×ULN; ALT \> 3×ULN; AST \>...
- Inability to swallow the research drug;
See the full eligibility criteria
- 18-80 years old, gender not limited;
- It conforms to the Western medical diagnosis of bronchiectasis;
- There has been no acute exacerbation or respiratory tract infection in the past 4 weeks. (Acute exacerbation is defined as the deterioration of three or more of the following six conditions: cough, changes in sputum...
- There have been at least two documented acute exacerbations in the past year, prescribed by doctors and diagnosed as signs and symptoms of respiratory tract infections;
- Pulmonary function tests can be conducted, and there is evidence of airflow limitation when screening vital capacity (FEV1/FVC ratio \<70%, and clinically stable at the time of entering the study);
- Voluntarily participate in this clinical trial and sign the informed consent form.
- Dry bronchiectasis mainly characterized by hemoptysis;
- Bronchiectasis caused by cystic fibrosis, allergic bronchopulmonary aspergillosis, etc;
- Previous respiratory diseases other than bronchiectasis (such as bronchial asthma, lung cancer, active pulmonary tuberculosis, interstitial lung disease, pulmonary thromboembolism and severe pneumonia, etc.);
- Combined with serious diseases of the heart, liver, kidneys, digestive system, blood system, etc., evaluated by the researcher, including but not limited to acute severe hepatitis, liver failure, liver cirrhosis, acute...
- Abnormal liver function was found in the patient screening examination, with the following criteria: total bilirubin \> 1.5×ULN; ALT \> 3×ULN; AST \> 3×ULN;
- Inability to swallow the research drug;
- Known allergy to the test drug;
- Participate in other clinical trials, use other research drugs or research devices within 30 days before randomization;
- Women or men of childbearing age refused to use contraceptive measures during the study period;
- Pregnant or lactating women;
- Any other factors that may not be suitable for participation in clinical research as determined by the researcher;
- In the past year, there has been a history of alcohol abuse, drug abuse or drug abuse;
- Other traditional Chinese medicine treatments were used within 7 days before the use of the study drug and during the study period.
The study team makes the final eligibility decision.
Where it's taking place
- Hangzhou, Zhejiang, China
- Huzhou, Zhejiang, China
- Jinhua, Zhejiang, China
- Yueqing, Zhejiang, China
- Zhoushan, Zhejiang, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hangzhou, Zhejiang, China; Huzhou, Zhejiang, China; Jinhua, Zhejiang, China; Yueqing, Zhejiang, China; Zhoushan, Zhejiang, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.